BioCentury
ARTICLE | Company News

India's IPAB rejects Gleevec patent application

July 8, 2009 2:15 AM UTC

India's Intellectual Property Appellate Board (IPAB) ruled against granting a patent for cancer drug Gleevec imatinib from Novartis AG (NYSE:NVS; SIX:NOVN). Upholding a 2006 decision by the Indian Con...